Federal Grant to Fund Acceleration of New Treatments for Rare Orphan Diseases. 

 

November 2010

 

Coralville, IA--Cellular Engineering Technologies (CET) Inc., a Coralville, Iowa, Biotechnology Company that develops commercial regenerative medicine products is one of 32 U.S. biotechnology companies that recently received a Federal grant from the Qualifying Therapeutic Discovery Project that was created by Congress. The purpose of the grant issued to CET will help to support the development of platform technologies in regenerative medicine and to accelerate discovery of new treatments for rare orphan diseases like Cystic Fibrosis, Muscular Dystrophy, Autism, Alpha 1 Anti-Trypsin Deficiency, Cystinosis and Lysosomal Storage Diseases.